BNP Paribas Asset Management
JANX icon

BNP Paribas Asset Management’s Janux Therapeutics JANX Stock Holding History

BNP Paribas Asset Management’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.8K Buy
852
+344
+68% +$4.72K ﹤0.01% 2165
2025
Q4 		$7K Buy
508
+137
+37% +$3.22K ﹤0.01% 2246
2025
Q3 		$9K Hold
371
– – ﹤0.01% 1669
2025
Q2 		$9K Buy
+371
New +$9.78K ﹤0.01% 1812

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BNP Paribas Asset Management's JANX Position: Q1 2026 in Review

BNP Paribas Asset Management increased its Janux Therapeutics (JANX) stake by 68% in Q1 2026, buying an estimated $4.72K and bringing the position to 852 shares worth $11.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2165.

BNP Paribas Asset Management first reported a position in JANX in Q2 2025 and has held it in 4 quarters since. 190 funds tracked by Wall St. Rank hold JANX as of Q1 2026.

  • BNP Paribas Asset Management held 852 shares of Janux Therapeutics worth $11.8K as of Q1 2026.
  • BNP Paribas Asset Management bought 344 Janux Therapeutics shares in Q1 2026, an estimated $4.72K.
  • Janux Therapeutics made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q1 2026, its #2165 holding.
  • BNP Paribas Asset Management first reported a position in Janux Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 190 funds tracked by Wall St. Rank held Janux Therapeutics as of Q1 2026.

Based on BNP Paribas Asset Management's 13F filing for Q1 2026, filed 14 May 2026.